Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Catriona Yale Sells 10,000 Shares of Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Catriona Yale sold 10,000 shares of the company’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $44.76, for a total value of $447,600.00. Following the sale, the insider now owns 95,034 shares of the company’s stock, valued at approximately $4,253,721.84. The trade was a 9.52 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Catriona Yale also recently made the following trade(s):

• On Wednesday, March 12th, Catriona Yale sold 614 shares of Akero Therapeutics stock. The stock was sold at an average price of $44.88, for a total transaction of $27,556.32.
• On Tuesday, February 18th, Catriona Yale sold 10,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $49.87, for a total transaction of $498,700.00.

Akero Therapeutics Stock Performance

NASDAQ:AKRO opened at $43.53 on Wednesday. The stock’s 50-day moving average is $42.78 and its 200-day moving average is $34.13. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05. Akero Therapeutics, Inc. has a 1-year low of $17.86 and a 1-year high of $58.40. The stock has a market cap of $3.47 billion, a P/E ratio of -11.61 and a beta of -0.19.

Akero Therapeutics (NASDAQ:AKRO) last issued its quarterly earnings results on Friday, February 28th. The company reported ($0.99) EPS for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.01). Equities research analysts anticipate that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts recently issued reports on AKRO shares. Morgan Stanley reiterated an “overweight” rating on shares of Akero Therapeutics in a research report on Sunday, March 2nd. Canaccord Genuity Group lifted their price target on Akero Therapeutics from $56.00 to $73.00 and gave the company a “buy” rating in a research note on Tuesday, January 28th. HC Wainwright boosted their price target on Akero Therapeutics from $72.00 to $75.00 and gave the stock a “buy” rating in a report on Monday, March 3rd. Bank of America raised Akero Therapeutics from a “neutral” rating to a “buy” rating and raised their price objective for the company from $35.00 to $63.00 in a research note on Thursday, January 30th. Finally, UBS Group boosted their target price on Akero Therapeutics from $42.00 to $109.00 and gave the stock a “buy” rating in a research note on Friday, January 31st. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Akero Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $76.29.

Institutional Investors Weigh In On Akero Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Victory Capital Management Inc. bought a new position in shares of Akero Therapeutics in the 3rd quarter worth about $211,000. LMR Partners LLP grew its stake in Akero Therapeutics by 17.0% during the third quarter. LMR Partners LLP now owns 20,597 shares of the company’s stock worth $591,000 after purchasing an additional 2,997 shares during the period. Intech Investment Management LLC bought a new stake in Akero Therapeutics in the third quarter worth approximately $491,000. Algert Global LLC lifted its stake in Akero Therapeutics by 8.3% in the third quarter. Algert Global LLC now owns 68,052 shares of the company’s stock valued at $1,952,000 after buying an additional 5,191 shares during the period. Finally, Summit Financial Wealth Advisors LLC bought a new position in shares of Akero Therapeutics during the 3rd quarter worth approximately $205,000.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.